论文部分内容阅读
目的 :检测原癌基因 C- erb B- 2蛋白和增殖细胞核抗原 (PCNA)在乳腺导管浸润癌中的表达及意义。方法 :对石蜡切片标本进行免疫组化染色。结果 :C- erb B- 2和 PCNA在乳腺导管浸润癌中阳性率为 74.3%和 68.6% ,二者表达与癌组织大小及分化程度呈正相关 (P<0 .0 5) ,与年龄、雌激素受体水平和生存期呈负相关 (P<0 .0 5)。与淋巴结有无转移无关 (P>0 .0 5)。结论 :C- erb B- 2和 PCNA过表达者预后不好、生存期短 ,尤其二者同时表达者预后更差。C- erb B- 2和 PCNA可作为判定乳腺导管浸润癌的恶性程度及预后的有效指标。
Objective: To detect the expression of C-erb B-2 protein and proliferating cell nuclear antigen (PCNA) in breast ductal invasive carcinoma and its significance. Methods: Paraffin sections were immunohistochemically stained. Results: The positive rates of C-erb B-2 and PCNA in invasive ductal carcinoma of the breast were 74.3% and 68.6%, respectively. The positive rates of C-erb B-2 and PCNA were positively correlated with the size and differentiation of cancer (P <0.05) Hormone receptor levels and survival were negatively correlated (P <0. 05). No lymph node metastasis (P> 0.05). Conclusions: The prognosis of C-erb B-2 and PCNA overexpression is poor, and the survival time is short. Especially, the expression of both C-erb B-2 and PCNA is worse at the same time. C-erb B-2 and PCNA can be used as a reliable indicator of malignancy and prognosis of breast ductal invasive carcinoma.